GLP-3 is a research peptide studied for its activity across GLP-1, GIP, and glucagon (GCG) receptor pathways, a multi-signalling model first explored by Eli Lilly.
Early clinical investigation reports meaningful effects on weight and metabolic biomarkers, with broader multi-pathway receptor engagement than earlier single-pathway GLP-1 research approaches. Research is ongoing to further define mechanisms and long-term translational relevance.
This compound is referenced strictly in the context of laboratory and pre-clinical research and is supplied for research purposes only, not for human consumption.

Reviews
There are no reviews yet.